Cargando…
Novel therapeutic choices in immune aplastic anemia
Aplastic anemia (AA) in its severe form has historically been associated with high mortality. With limited supportive care and no effective strategy to reverse marrow failure, most patients diagnosed with severe AA (SAA) died of pancytopenia complications. Since the 1970s, hematopoietic stem cell tr...
Autor principal: | Scheinberg, Phillip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484718/ https://www.ncbi.nlm.nih.gov/pubmed/32953089 http://dx.doi.org/10.12688/f1000research.22214.1 |
Ejemplares similares
-
TERC haploid cell reprogramming: a novel therapeutic strategy for aplastic anemia
por: Tang, Xinyu, et al.
Publicado: (2023) -
Aplastic Anemia in China
por: Liu, Chunyan, et al.
Publicado: (2018) -
Idiopathic Aplastic Anemia: An Update
por: Solomou, Elena E.
Publicado: (2019) -
Recent advances in treatment of aplastic anemia
por: Shin, Seung Hwan, et al.
Publicado: (2014) -
Stem cell transplantation in aplastic anemia: Impact on choices for first line therapy
por: Bacigalupo, Andrea, et al.
Publicado: (2019)